Cargando…

Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity

Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthoracic echocardiography have limited sensitivity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinxin, Sun, Yuxi, Zhang, Yanli, Fang, Fengqi, Liu, Jiwei, Xia, Yunlong, Liu, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696384/
https://www.ncbi.nlm.nih.gov/pubmed/36354771
http://dx.doi.org/10.3390/jcdd9110372
_version_ 1784838304365019136
author Zhang, Xinxin
Sun, Yuxi
Zhang, Yanli
Fang, Fengqi
Liu, Jiwei
Xia, Yunlong
Liu, Ying
author_facet Zhang, Xinxin
Sun, Yuxi
Zhang, Yanli
Fang, Fengqi
Liu, Jiwei
Xia, Yunlong
Liu, Ying
author_sort Zhang, Xinxin
collection PubMed
description Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthoracic echocardiography have limited sensitivity and specificity for the early detection of myocardial injury. Cardiovascular imaging generally detects cancer therapy-related cardiac dysfunction (CTRCD) at advanced stages, whereas biomarkers are inexpensive, easily detected, reproducible, and capable of detecting even minimal cardiomyocyte damage or mild hemodynamic fluctuations. The presence of circulating cardiac biomarkers has been investigated as early indicators of cardiotoxicity and predictors of subsequent CTRCD. Currently, the most frequently used cardiac biomarkers are cardiac troponin (cTn) and natriuretic peptides (NPs). This review presents the evidence gathered so far regarding the usefulness and limitations of cardiac biomarkers in the field of cardio-oncology.
format Online
Article
Text
id pubmed-9696384
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96963842022-11-26 Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity Zhang, Xinxin Sun, Yuxi Zhang, Yanli Fang, Fengqi Liu, Jiwei Xia, Yunlong Liu, Ying J Cardiovasc Dev Dis Review Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthoracic echocardiography have limited sensitivity and specificity for the early detection of myocardial injury. Cardiovascular imaging generally detects cancer therapy-related cardiac dysfunction (CTRCD) at advanced stages, whereas biomarkers are inexpensive, easily detected, reproducible, and capable of detecting even minimal cardiomyocyte damage or mild hemodynamic fluctuations. The presence of circulating cardiac biomarkers has been investigated as early indicators of cardiotoxicity and predictors of subsequent CTRCD. Currently, the most frequently used cardiac biomarkers are cardiac troponin (cTn) and natriuretic peptides (NPs). This review presents the evidence gathered so far regarding the usefulness and limitations of cardiac biomarkers in the field of cardio-oncology. MDPI 2022-10-29 /pmc/articles/PMC9696384/ /pubmed/36354771 http://dx.doi.org/10.3390/jcdd9110372 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhang, Xinxin
Sun, Yuxi
Zhang, Yanli
Fang, Fengqi
Liu, Jiwei
Xia, Yunlong
Liu, Ying
Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
title Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
title_full Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
title_fullStr Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
title_full_unstemmed Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
title_short Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
title_sort cardiac biomarkers for the detection and management of cancer therapy-related cardiovascular toxicity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696384/
https://www.ncbi.nlm.nih.gov/pubmed/36354771
http://dx.doi.org/10.3390/jcdd9110372
work_keys_str_mv AT zhangxinxin cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity
AT sunyuxi cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity
AT zhangyanli cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity
AT fangfengqi cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity
AT liujiwei cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity
AT xiayunlong cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity
AT liuying cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity